Early Mortality and Loss to Follow-up in HIV-Infected Children Starting Antiretroviral Therapy in Southern Africa

childhood mortality Male Malawi nevirapine HIV Infections preschool child 310 Severity of Illness Index South Africa 0302 clinical medicine sensitivity analysis Risk Factors Antiretroviral Therapy, Highly Active Child Southern Mozambique child lopinavir plus ritonavir article Age Factors efavirenz Human immunodeficiency virus infected patient Prognosis 3. Good health female priority journal risk factor Child, Preschool Female Zimbabwe Anti-HIV Agents Antiretroviral Therapy CD4 lymphocyte percentage Africa, Southern 03 medical and health sciences male Human immunodeficiency virus infection follow up Humans Highly Active human Preschool Infant school child lamivudine plus stavudine infant major clinical study CD4 Lymphocyte Count adolescent Africa
DOI: 10.1097/qai.0b013e3181e0c4cf Publication Date: 2010-06-29T07:37:04Z
ABSTRACT
Many HIV-infected children in Southern Africa have been started on antiretroviral therapy (ART), but loss to follow up (LTFU) can be substantial. We analyzed mortality in children retained in care and in all children starting ART, taking LTFU into account.Children who started ART before the age of 16 years in 10 ART programs in South Africa, Malawi, Mozambique, and Zimbabwe were included. Risk factors for death in the first year of ART were identified in Weibull models. A meta-analytic approach was used to estimate cumulative mortality at 1 year.Eight thousand two hundred twenty-five children (median age 49 months, median CD4 cell percent 11.6%) were included; 391 (4.8%) died and 523 (7.0%) were LTFU in the first year. Mortality at 1 year was 4.5% [95% confidence interval (CI): 2.8% to 7.4%] in children remaining in care, but 8.7% (5.4% to 12.1%) at the program level, after taking mortality in children and LTFU into account. Factors associated with mortality in children remaining in care included age [adjusted hazard ratio (HR) 0.37; 95% CI: 0.25 to 0.54 comparing > or =120 months with <18 months], CD4 cell percent (HR: 0.56; 95% CI: 0.39 to 0.78 comparing > or =20% with <10%), and clinical stage (HR: 0.12; 95% CI: 0.03 to 0.45 comparing World Health Organization stage I with III/IV).In children starting ART and remaining in care in Southern Africa mortality at 1 year is <5% but almost twice as high at the program level, when taking LTFU into account. Age, CD4 percentage, and clinical stage are important predictors of mortality at the individual level.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (29)
CITATIONS (79)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....